Literature DB >> 27573630

Treatment of Schistosomiasis in a Patient Allergic to Praziquantel: A Desensitization and Treatment Protocol.

Trupti A Patel1, Joanna Lukawska2, Jennifer Rowe3, Robin L Bailey1.   

Abstract

Praziquantel is the mainstay of treatment of Schistosomiasis, which affects at least 262 million people worldwide. It is also used in the treatment of other trematode as well as cestode infections, with few safe and effective alternatives. It is generally well tolerated and allergic reactions are rare. In this report, we present a case of schistosomiasis with a history of a hypersensitivity reaction to praziquantel. Skin-prick and intradermal testing were performed, followed by treatment through rapid desensitization. This protocol may be of value to those patients requiring praziquantel treatment with a history of IgE-mediated allergy to the drug. © The American Society of Tropical Medicine and Hygiene.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27573630      PMCID: PMC5094214          DOI: 10.4269/ajtmh.16-0462

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  18 in total

1.  A clinical approach to a patient with praziquantel hypersensitivity.

Authors:  S W Huang
Journal:  J Allergy Clin Immunol       Date:  1992-11       Impact factor: 10.793

Review 2.  Praziquantel.

Authors:  P Andrews; H Thomas; R Pohlke; J Seubert
Journal:  Med Res Rev       Date:  1983 Apr-Jun       Impact factor: 12.944

3.  [Allergic manifestation after pyquiton treatment of schistosomiasis].

Authors:  T Liu
Journal:  Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi       Date:  1984

4.  Alternative algorithm for L-asparaginase allergy in children with acute lymphoblastic leukemia.

Authors:  Ozge Uysal Soyer; Selin Aytac; Ayfer Tuncer; Mualla Cetin; Sevgi Yetgin; Bulent Enis Sekerel
Journal:  J Allergy Clin Immunol       Date:  2008-12-10       Impact factor: 10.793

5.  Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases.

Authors:  Mariana C Castells; Nichole M Tennant; David E Sloane; F Ida Hsu; Nora A Barrett; David I Hong; Tanya M Laidlaw; Henry J Legere; Samridhi N Nallamshetty; Ross I Palis; Jayanti J Rao; Suzanne T Berlin; Susana M Campos; Ursula A Matulonis
Journal:  J Allergy Clin Immunol       Date:  2008-05-27       Impact factor: 10.793

6.  A case of anaphylactic reaction to praziquantel treatment.

Authors:  Chenghua Shen; Min-Ho Choi; Young Mee Bae; Gui Yu; Shuhua Wang; Sung-Tae Hong
Journal:  Am J Trop Med Hyg       Date:  2007-03       Impact factor: 2.345

Review 7.  Human schistosomiasis.

Authors:  Daniel G Colley; Amaya L Bustinduy; W Evan Secor; Charles H King
Journal:  Lancet       Date:  2014-04-01       Impact factor: 79.321

Review 8.  A review of clinical experience with oxamniquine.

Authors:  R Foster
Journal:  Trans R Soc Trop Med Hyg       Date:  1987       Impact factor: 2.184

Review 9.  Systematic review and meta-analysis of artemisinin based therapies for the treatment and prevention of schistosomiasis.

Authors:  Luis Pérez del Villar; Francisco J Burguillo; Julio López-Abán; Antonio Muro
Journal:  PLoS One       Date:  2012-09-21       Impact factor: 3.240

10.  Changes in IgE- and antigen-dependent histamine-release in peripheral blood of Schistosoma mansoni-infected Ugandan fishermen after treatment with praziquantel.

Authors:  Mohamed Z Satti; Pierre Cahen; Per S Skov; Sarah Joseph; Frances M Jones; Colin Fitzsimmons; Karl F Hoffmann; Claus Reimert; H Curtis Kariuki; Francis Kazibwe; Joseph K Mwatha; Gachuhi Kimani; Birgitte J Vennervald; John H Ouma; Narcis B Kabatereine; David W Dunne
Journal:  BMC Immunol       Date:  2004-04-21       Impact factor: 3.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.